Table 5.
Multivariate analysis of clinicopathological factors for 2 year progression-free survival (PFS) of 85 patients with ESCC
| Characteristics | Category | RR (95%CI) | P-value |
|---|---|---|---|
| Age |
≥60 vs <60 years |
1.500 (0.626-3.596) |
0.363 |
| Tumor differentiation |
Poor vs Well/Moderate |
1.607 (0.658-3.925) |
0.296 |
| T status |
T3 ~ 4 vs T1 ~ 2 |
1.963 (0.814-4.733) |
0.131 |
| Lymph metastasis |
N1/N2/N3vs N0 |
3.111 (1.276-7.583) |
0.011* |
| Clinical stage |
III/IV vs I/II |
3.046 (1.255-7.395) |
0.013* |
| STC-1 expression in PB and/or BM |
Positive vs Negtive |
3.348 (1.372-8.172) |
0.007* |
| KPS scores | ≥90 vs < 90 | 0.691 (0.281-1.703) | 0.422 |
RR: Relative risk; PB: peripheral blood; BM: bone marrow; KPS: Karnofsky performance status.
*P < 0.05.